

SUPPLEMENTARY MATERIAL

Table S1. Search strategy

Search strategy	Date
<p>OVID (MEDLINE, EMBASE, COCHRANE, AMED)</p> <ol style="list-style-type: none"> 1. Longitudinal stud*.mp. [mp=ab, hw, ti, tx, kw, ct, ot, sh, tn, dm, mf, dv, fx, dq, nm, kf, ox, px, rx, ui, sy] 2. Prospective Stud*.mp. [mp=ab, hw, ti, tx, kw, ct, ot, sh, tn, dm, mf, dv, fx, dq, nm, kf, ox, px, rx, ui, sy] 3. Follow-up stud*.mp. [mp=ab, hw, ti, tx, kw, ct, ot, sh, tn, dm, mf, dv, fx, dq, nm, kf, ox, px, rx, ui, sy] 4. Prognosis.mp. [mp=ab, hw, ti, tx, kw, ct, ot, sh, tn, dm, mf, dv, fx, dq, nm, kf, ox, px, rx, ui, sy] 5. Survival.mp. [mp=ab, hw, ti, tx, kw, ct, ot, sh, tn, dm, mf, dv, fx, dq, nm, kf, ox, px, rx, ui, sy] 6. Survival analysis.mp. [mp=ab, hw, ti, tx, kw, ct, ot, sh, tn, dm, mf, dv, fx, dq, nm, kf, ox, px, rx, ui, sy] 7. Logistic model*.mp. [mp=ab, hw, ti, tx, kw, ct, ot, sh, tn, dm, mf, dv, fx, dq, nm, kf, ox, px, rx, ui, sy] 8. Proportional hazards model*.mp. [mp=ab, hw, ti, tx, kw, ct, ot, sh, tn, dm, mf, dv, fx, dq, nm, kf, ox, px, rx, ui, sy] 9. Disease Progression.mp. [mp=ab, hw, ti, tx, kw, ct, ot, sh, tn, dm, mf, dv, fx, dq, nm, kf, ox, px, rx, ui, sy] 10. Life Table*.mp. [mp=ab, hw, ti, tx, kw, ct, ot, sh, tn, dm, mf, dv, fx, dq, nm, kf, ox, px, rx, ui, sy] 11. cohort stud*.mp. [mp=ab, hw, ti, tx, kw, ct, ot, sh, tn, dm, mf, dv, fx, dq, nm, kf, ox, px, rx, ui, sy] 12. prognos*.mp. [mp=ab, hw, ti, tx, kw, ct, ot, sh, tn, dm, mf, dv, fx, dq, nm, kf, ox, px, rx, ui, sy] 13. course.mp. [mp=ab, hw, ti, tx, kw, ct, ot, sh, tn, dm, mf, dv, fx, dq, nm, kf, ox, px, rx, ui, sy] 14. inception.mp. [mp=ab, hw, ti, tx, kw, ct, ot, sh, tn, dm, mf, dv, fx, dq, nm, kf, ox, px, rx, ui, sy] 15. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 16. COVID-19.mp. [mp=ab, hw, kw, ti, ot, tx, ct, sh, tn, dm, mf, dv, fx, dq, nm, kf, ox, px, rx, an, ui, sy] 17. Coronavirus disease.mp. [mp=ab, hw, kw, ti, ot, tx, ct, sh, tn, dm, mf, dv, fx, dq, nm, kf, ox, px, rx, an, ui, sy] 18. nCov.mp. [mp=ab, hw, kw, ti, ot, tx, ct, sh, tn, dm, mf, dv, fx, dq, nm, kf, ox, px, rx, an, ui, sy] 19. 19nCov.mp. [mp=ab, hw, kw, ti, ot, tx, ct, sh, tn, dm, mf, dv, fx, dq, nm, kf, ox, px, rx, an, ui, sy] 20. novel coronavirus.mp. [mp=ab, hw, kw, ti, ot, tx, ct, sh, tn, dm, mf, dv, fx, dq, nm, kf, ox, px, rx, an, ui, sy] 21. novel coronavirus 2019.mp. [mp=ab, hw, kw, ti, ot, tx, ct, sh, tn, dm, mf, dv, fx, dq, nm, kf, ox, px, rx, an, ui, sy] 22. Whuan coronavirus.mp. [mp=ab, hw, kw, ti, ot, tx, ct, sh, tn, dm, mf, dv, fx, dq, nm, kf, ox, px, rx, an, ui, sy] 23. Whuan pneumonia.mp. [mp=ab, hw, kw, ti, ot, tx, ct, sh, tn, dm, mf, dv, fx, dq, nm, kf, ox, px, rx, an, ui, sy] 24. Sars-CoV-2.mp. [mp=ab, hw, kw, ti, ot, tx, ct, sh, tn, dm, mf, dv, fx, dq, nm, kf, ox, px, rx, an, ui, sy] 25. Severe acute respiratory syndrome.mp. [mp=ab, hw, kw, ti, ot, tx, ct, sh, tn, dm, mf, dv, fx, dq, nm, kf, ox, px, rx, an, ui, sy] 26. 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 27. 15 and 26 28. limit 27 to yr="2019 -Current" 	<p>Conducted up to June 28th, 2021.</p>

Table S2. List of studies excluded at full-text screening stage with brief reasons

Autor	Year	Journal paper?	Full text available?	1. Prospective cohort?	Reason 1	2. Population?	Reason 2	3. Outcome?	Reason 3	Comments
Abbas	2020			N	Cross-sectional/ Retrospective study					
Abdulaal	2020			N	Retrospective study					
Abohamr	2020			N	Descriptive case series					
Abolghasemi	2020	Letter				N	No inception cohort			
Abraham	2020									
Abrishami	2020					N	No inception cohort			
Aguila-Gordo	2021			N	Retrospective study					
Ali	2020			N	Retrospective study					
Alisadehsani	2020					N	Included diagnosis for CT			
Allameh	2020			N	Retrospective study					
Allwood	2020	Protocol								
Al-Salameh	2020			N	Retrospective study					
Al-Salameh	2021			N	Retrospective study					
Alser	2021	Conference Abstract								
Al-Sulaiman	2021					N	No inception cohort			
Alvarez-Maldonado	2021					N	No inception cohort			
Andres-Esteban	2021					N	No inception cohort			
Apea	2021					N	Included people <18 y			
Arentz	2020	Letter								
Aries	2021		N							
Arnold	2020					N	No inception cohort			
Asch	2020					N	No inception cohort			
Auld	2020			N	Retrospective study					
Aw	2020					N	Included diagnosis for CT			
Aydin	2020					N	Included diagnosis for CT			

Bahier	2020					N	Included no hospitalized patients			
Baiardo Redaelli	2021					N	No inception cohort			
Baktash	2020					N	Included diagnosis for x-ray			
Baqi	2021			N	Retrospective study					
Baumer	2020					N	Included suspected or confirmed COVID-19			
Bayrak	2021					N	No inception cohort			
Becchetti	2020					N	No inception cohort			
Bels	2020					N	Included diagnosis for CT			
Berenguer	2021			N	Retrospective study					
Beunier	2020					N	Included diagnosis for CT and clinical symptoms			
Bezerra	2021			N	Retrospective study					
Bezzio	2020					N	Included diagnosis for CT and clinical symptoms			
Bloom	2020					N	No inception cohort			
Booth	2020						Included clinical and radiological diagnosis			
Bousquet	2020					N	Included radiological diagnosis			
Bradley	2020					N	No inception cohort			
Brar	2020			N	Retrospective study					
Brenner	2020					N	Included people <18 y			
Brieghel	2021			N	Retrospective study					
Budhi	2020	Conference Abstract								
Burrel	2020					N	Included people <18 y			
Cagnazzo	2020					N	No inception cohort			
Calik Basaran	2021					N	Included non confirmed COVID-19			
Calvo-Fernandez	2020					N	No inception cohort			
Cariou	2020					N	Included clinical/radiological diagnosis			

Carter	2020					N	Included clinical/radiological diagnosis			
Chaibi	2020			N	Retrospective study					
Chen	2020			N	Retrospective study					
Chew	2021			N	Retrospective study					
Ciceri	2020					N	Included radiological diagnosis			
Coca	2020					N	No inception cohort			
Conway	2020					N	No inception cohort			
Covino	2021					N	No inception cohort			
Crespo	2020					N	Included no hospitalized people			
Daifi	2020			N	Retrospective study					
Dang	2020	Conference Abstract								
De Roubin	2021			N	Retrospective study					
De Souza	2021					N	Included people <18 y			
de-Azambuja	2020					N	Included diagnosis for CT and clinical symptoms			
Dobre	2021					N	No inception cohort			
Doyen	2020					N	No inception cohort			
Drake	2020			N	Retrospective study					
Du	2020					N	Included clinical diagnosis			
Dushimova	2020	Conference Abstract								
Elhadi	2021					N	No inception cohort			
Elkrief	2020					N	No inception cohort			
El-Solh	2021			N	Retrospective study					
Fadulelmola	2020			N	Retrospective study					
Farre	2020					N	No inception cohort			
Favalli	2020					N	No inception cohort			
Fenioux	2021					N	No inception cohort			
Fernandez-Capitan	2020					N	No inception cohort			

Fernandez-Capitan	2021					N	No inception cohort			
Ferrando-Vivas	2021					N	No inception cohort			
Figueroa-Pena	2020					N	No inception cohort			
Flaatten	2021					N	No inception cohort			
Fominskiy	2021					N	Included diagnosis for CT and clinical symptoms			
Forest	2020			N	Retrospective study					
Frager	2020					N	No inception cohort			
Fried	2020					N	No inception cohort			
Fried	2021					N	No inception cohort			
Frontera	2020					N	No inception cohort			
Fuentes Antras	2020					N	No inception cohort			
Gadotti	2020					N	Included inception > 10 days of onset symptoms			
Garcia-Vidal	2021					N	No inception cohort			
Gavrilina	2020					N	No inception cohort			
Georges	2020			N	Clinical trial					
Geretti	2020					N	No inception cohort			
Gessler	2021					N	No inception cohort			
Ghio	2020			N	Retrospective study					
Giacomelli	2021									Duplicate data
Gil-Rodrigo	2020					N	Included clinical diagnosis			
Glasbey	2020					N	No inception cohort			
Glenthoj	2020					N	Included no hospitalized people			
Haase	2020			N	Retrospective study					
Haberman	2020					N	Included non confirmed COVID-19			
Hagg	2020					N	Included non confirmed COVID-19			
Hayek	2020					N	No inception cohort			
Heberto	2020					N	No inception cohort			
Hernandez-Rubio	2020					N	No inception cohort			
Hewitt	2020					N	Included clinical diagnosis			
Hicini	2020					N	Included asymptomatics people			

Hirsch	2020			N	Retrospective study					
Hittersdorf	2020			N	Retrospective study					
Hollein	2020	Letter								
Iftimie	2020					N	No inception cohort			
Inciardi	2020					N	No inception cohort			
Jaspard	2021					N	Included people <18 y			
Karbalai	2020			N	Retrospective study					
Kasivisvanathan	2020					N	Patients no hospitalized by COVID-19			
Kates	2020					N	No inception cohort			
Ken-Dror	2020					N	No inception cohort			
Khalil	2020					N	No inception cohort			
Khalili	2020					N	No inception cohort			
Khan	2020			N	Retrospective study					
Khan	2020					N	No inception cohort			
Khan	2020					N	No inception cohort			
Kirenga	2020					N	Included people <18 y			
Kjeldsen	2021					N	No inception cohort			
Knopp	2020					N	No inception cohort			
Knox	2021					N	No inception cohort			
Kocay	2020					N	No inception cohort			
Kocayigit	2021					N	No inception cohort			
Kotflors	2020			N	Retrospective study					
Kragholm	2020					N	No hospitalized people			
Kristinsson	2020					N	No inception cohort			
Kundi	2020					N	No inception cohort			
Kurtz	2021					N	No inception cohort			
Laake	2021					N	No inception cohort			
Lambermont	2021					N	No inception cohort			
Laosa	2020					N	No inception cohort			
Lassen	2020					N	No inception cohort			
Lee	2020			N	Retrospective study					
Li	2020			N	Retrospective study					
Li	2020			N	Retrospective study					
Li	2021					N	No inception cohort			

Liu	2020					N	No hospitalized people			
Liu	2020					N	No inception cohort			
Long	2020					N	No inception cohort			
Lopez-Otero	2020					N	No inception cohort			
Lowe	2021			N	Retrospective study					
Ma	2020					N	No inception cohort			
Mandel	2020					N	No inception cohort			
Manocha	2020			N	Retrospective study					
Marcolino	2021			N	Retrospective study					
Marengoni	2020			N	Retrospective study					
Martin-Sanchez	2020			N	Retrospective study					
Mato	2020					N	No inception cohort			
Mattar	2020					N	Patients no hospitalized by COVID-19			
Mehta	2020					N	Included asymptomatics people			
Mendizabal	2020					N	Included asymptomatics people			
Mendizabal	2020	Conference Abstract								
Messika	2020			N	Retrospective study					
Miles	2020					N	Included non confirmed COVID-19			
Mithal	2020					N	No inception cohort			
Mody	2021					N	No inception cohort			
Munoz	2020			N	Retrospective study					
Nabors	2021		N							
Nadeen	2020	Letter								
Nemer	2020					N	No inception cohort			
Nemer	2021			N	Retrospective study	N	No inception cohort			
Nunez-Gil	2020					N	No inception cohort			
Ozer	2021			N	Retrospective study					
Patel	2021					N	No inception cohort			
Peng	2021			N	Retrospective study					
Perez-Segura	2021			N	Retrospective study					

Peterlana	2020	Conference abstract								
Petrilli	2020					N	No inception cohort			
Petrulewicz	2020					N	No inception cohort			
Pinto	2020					N	No inception cohort			
Plotnikow	2020					N	No inception cohort			
Potalivo	2020					N	No inception cohort			
Price	2020	Protocol								
Raad	2020	Conference abstract								
Rahim	2020			N	Cross-sectional study					
Richards-Belle	2020					N	No inception cohort			
Robinson	2020					N	No inception cohort			
Rodriguez-Lago	2020					N	No inception cohort			
Rubio-Rivas	2020			N	Retrospective study					
Sachdeva	2020					N	No inception cohort			
Salvador	2021					N	No inception cohort			
Sami	2020					N	No inception cohort			
Santus	2020					N	No inception cohort			
Sarfaraz	2021					N	Included asymptomatic people			
Savasi	2020					N	Included asymptomatics people			
Seiglie	2020					N	No inception cohort			
Serling-Boyd	2020					N	Included no hospitalized people			
Sharma	2021					N	Included people <18 y			
Shwerzmann	2021					N	Included diagnosis for CT and clinical symptoms			
Skorin	2020					N	No inception cohort			
Smati	2020			N	Retrospective study					
Snipelilisk	2020		N							
Stockenhuber	2020					N	No inception cohort			
Sy	2020					N	Included no hospitalized people			
Tadolini	2020					N	No inception cohort			
Taramasso	2020			N	Retrospective study					
Tatum	2020					N	No inception cohort			
Tehrani	2020			N	Retrospective study					

Tomasoni	2020			N	Retrospective study					
Trabulus	2020					N	No inception cohort			
Vaid	2020			N	Retrospective study					
Vizcarra	2020					N	Included suspected cases of COVID-19			
Vlachos	2021					N	Data on symptom onset were missing			
Vrsalovic	2020	Letter								
Vuagnat	2020					N	Included non hospitalized people			
Wang	2020					N	No inception			
Wang	2020			N	Retrospective study					
Wang	2021					N	Included people <18 y			
Webb	2020					N	Included non hospitalized people			
Wendel	2020					N	Included people <18 y			
Yang	2020					N	No inception cohort			
Yehia	2020			N	Retrospective study					
Zeng	2020			N	Retrospective study					
Zhang	2020					N	Diagnosis not described			
Zhang	2020			N	Retrospective study					
Zhang	2021			N	Retrospective study					
Zhao	2020			N	Retrospective study					
Zinellu	2020			N	Retrospective study					
Zorzi	2020			N	Retrospective study					
Zuccon	2020			N	Retrospective study					

Abbreviations: N=Not; CT=computed tomography.

Table S3. Table of characterization

Study	Country	Sample size	Age Mean (SD) or Median (IQR)	Sex No (%)	Hospital setting	Comorbidities No (%)	Onset of symptoms Days median (IQR)	Outcomes No (%) Days median (IQR)
Allenbach et al., (2020) ²⁰	France	152	77 (60–83)	Male 91 (59.9) Female 61 (40.13)	Hospital (17 to ICU)	Smoker 10 (6.6), HBP 82 (53.9), DM 37 (24.3), DLP 50 (32.9), IHD 35 (23), Cancer 30 (19.7), COPD 12/151 (7.9)	5 (2-8)	Mortality: 32 (21.9), 14 days Recovery: 84 (57.5)
Barrasa et al. (2020) ³⁴	Spain	48	63 (51–75)	Male 27 (56) Female 21 (44)	ICU	Obesity 23 (48), HBP 21 (44), DM 9 (19), Smoker 9 (19), HT 9 (19), HD 5 (10), Immunosuppression 3 (6), COPD 18 (38), solid organ transplant 1 (2)	7 (5–12)	Mortality: 6 (13) 7 days, 14 (31), 15 days
Brandão et al. (2021) ¹⁴	Brazil	506	59.2 (±16.8)	Male 290 (57.3) Female 216 (42.7)	Hospital (300 to ICU)	HBP 280 (55.3%); diabetes 181 (35.8); smoking history 144 (39.2%); renal replacement therapy 15 (3.0%); Congestive heart failure 39 (7.7%); COPD 15 (3.0%); asthma 22 (4.4%); Other lung diseases 12 (2.4%); cancer 39 (7.7%); solid organ transplant 16 (3.2%); systemic lupus erythematosus 5 (1.0%); HIV 7 (1.4%).	<10	Mortality: 153 (30.2), 21 days Recovery: 333 (65.9)
Cao et al. (2020) ¹⁵	China	102	54 (37–67)	Male 53 (52) Female 49 (48)	Hospital (18 to ICU)	DM 11 (10.8), HBP 28 (27.5), CVD 5 (4.9) CRD 10 (9.8), cerebrovascular disease 6 (5.9), malignancy 4 (3.9), CKD 4 (3.9), CLD 2 (2.0)	6 (3–7)	Mortality: 17 (16.6), 15 (9–21) days Morbidity: Shock 10 (9.8), ARDS 20 (19.6) Recovery: 85 (83.3)
Cortes-Telles et al. (2020) ²²	México	200	55 (41–65)	Male 138 (69) Female 62 (31)	Hospital (44 to ICU)	Obesity (52), HBP (30), DM (28)	8 (6–9)	Mortality: 77 (38), 8 (4–16)
Cummings et al. (2020) ⁴³	United States	257	62 (51–72)	Male 171 (67) Female 86 (33)	ICU	DM 92 (36) HBP 162 (63), CHD 49 (19), COPD or ILD 24 (9), asthma 21 (8), smoking history 33 (13), chronic neurological disease or dementia 24 (9), cancer (7), CKD 37 (14), LC 5 (2), solid organ transplant recipient 10 (4), HIV 8 (3)	5 (2-7)	Mortality: 101 (39), 9 (5–15) days Recovery: 58 (23)
Dzupová et al. (2021) ²⁸	Zech Republic	74	67.5 (56-75)	Male 46 (62.2) Female 28 (37.8)	ICU	CRD 17 (23.0); COPD only 7 (9.5); immunodeficiency 6 (8.1); diabetes 30 (40.5); HBP 48 (64.9); CAD 16 (21.6); CKD 10 (13.5); CLD 5 (6.8); Cancer 7 (9.5); Obesity 61 (82.5)	6 (4–8)	Mortality: 30 (40.5) Morbidity: ARDS 57 (77.0) Recovery: 31 (41.9)
Estella et al. (2021) ³³	Spain	422	63 (54-71)	Male 305 (72.3) Female 117 (27.7)	ICU	COPD 25 (5.9), CKD 44 (10.4), cirrhosis 11 (2.6), cancer 30 (7.1)	7 (4-9)	Mortality: 152 (36.5), 42 days
Ferrando et al. (2020) ³⁸	Spain and Andorra	663	64 (56-72) No=661	Male 441 (66.7) Female 219 (33.18) No=660	ICU	HBP 329 (49.6), DM 151 (22.7), CHD 9 (1.3), CKD 38 (5.7), asthma 17 (2.5), COPD 28 (4.2), DLP 90 (13.5), cancer 23 (3.4)	7 (5-9)	Mortality: 203 (30.6), 80 days Morbidity: SDRA 601 (90.6), Shock 150 (22.6)

Giacomelli et al. (2020) ²¹	Italy	233	61 (50–72)	Male 161 (69.1) Female 72 (30.9)	Hospital and ICU (145 – mild and moderate, 88 – severe and critical)	Smoking history 70 (30), obesity 38 (16.3)	7 (4–9)	Mortality: 48 (20.6), 11 (6–18) days Recovery: 162 (69.5)
Gupta et al. (2020) ⁴¹	United States	2215	60.5 (14.5)	Male 1436 (64.8) Female 779 (35.2)	ICU	DM 861 (38.9), HBP 1322 (59.7), CAD 288 (13.0), CHF 196 (8.8), CLD 531 (24.0), COPD 173 (7.8), asthma 258 (11.6), smoking history 656 (29.6), CKD 280 (12.6), end-stage KD 64 (2.9), malignancy 112 (5.1), immunodeficiency 65 (2.9)	7 (4-10)	Mortality: 875 (39.5); 16 (8-28) Morbidity: Respiratory failure 727 (92.7), Septic shock 311 (39.7) Recovery: 1.203 (54.3)
Jourdes et al. (2020) ¹⁸	France	263	65 (54–76)	Male 155 (58.9) Female 108 (41.06)	Hospital (111 to ICU)	Overweight 88/244 (36.1), obesity 69/244 (28.3) HBP 104 (39.5), DM 52 (19.8), HD 35 (13.3) cerebrovascular disease 17 (6.5), CRD 57 (21.6), CKD 24 (9.1), CLD 2 (0.8), malignancy 27 (10.3), immunosuppression 24 (9.1) smokers 11/115 (9.3)	7 (4–10)	Mortality: 19, 14 days Recovery: 173, 14 days
Kaeuffer et al. (2020) ¹⁹	France	1045	66 (20–100)	Male 612 (59) Female 433 (41.4)	Hospital (335 to ICU)	HBP 548 (52.4), DM 264 (25.3), smoker 36 (3.4), CHF 121 (11.6), CRD 172 (16.5), CKD 117 (11.2), CLD 11 (1.1), immunosuppression 48 4.6, cancer 109 (10.4), pregnancy 15 (1.4)	7.2 (5.3)	Mortality: 115 (11), 7 days, 195 (18.7), 30 days Morbidity: 335 (32.1) Recovery: 155 (14.8)
Kayina et al. (2020) ³⁰	India	235	50.7±15.1	Male 160 (68.1) Female 75 (31.91)	ICU	HBP 65, DM 54, CAD 13, CKD 22, CLD 10, COPD 5, cancer 26	4 (2-5)	Mortality: 20, 1 day
Larsson et al. (2020) ³⁹	Sweden	260	59 (51-65)	Male 208 (80.0) Female 52 (20)	ICU	HBP 103 (39.6), CHD 17 (6.5), COPD/asthma 33 (12.7), immunodeficiency 15 (5.8), CLD 1 (0.4), CKD 4 (1.5), DM 68 (26.2), neuromuscular disease 3 (1.2)	11 (8-14)	Mortality: 60, 12 days (6-18) Recovery: 62 (23.9)
Madsen et al. (2021) ¹⁷	Denmark	83	62 (54-74)	Male 52 (62.7) Female 31 (37.3)	Hospital (13 transfer for ICU)	CVD 46 (55.4), HBP 35 (42.2), stroke 4 (4.8), CRD 14 (16.9), malignancy 14 (16.9), DM 13 (15.7), inflammatory bowel disease 3 (3.6), rheumatoid arthritis 3 (3.6), CKD 2 (2.4)	9 (5.5-11)	Mortality: 4, 10 days (6.5-13) Morbidity: ARDS, 28 (33.7) Recovery: 78 (94)
Molnar et al. (2020) ⁴²	United States	386	60 (51-70)	Male 277 (72) Female 109 (28)	ICU	DM 253 (66), HBP 317 (82), CAD 104 (27), CHF 71 (18), atrial fibrillation or atrial flutter 48 (12), COPD 21 (5), asthma 23 (6), smoking history 117, CKD 198 (51), CLD 35 (9), HIV 10 (3), cancer 25 (6)	5 (3-8)	Mortality: 163, 28 days Morbidity: ARDS, 52, Septic shock, 26
Myrstad et al. (2020) ²⁴	Norway	66	71.5 (30–95)	Male 38 (58) Female 28 (42)	Hospital (7 transfer to ICU)	HBP 4 (27), DM 3 (20), CKD 2 (13), Malignancy 3 (20), COPD 4 (27)	6.9 (3.8) 8.7 (5.0)	Mortality: 13 (20), 5 days Recovery: 53 (80)
Namendys-Silva et al. (2021) ³²	Mexico	164	57.3 (SD 13.7)	Male 114 (69.5) Female 50 (30.48)	ICU	HBP 63 (38.4), DM 53 (32.3), smoker 24 (14.3), solid tumors 10 (6.0), COPD 4 (2.4), CKD 6 (3.6)	7 (4.5-9)	Mortality: 85 (51.8), 30 days


Olivas-Martínez et al. (2021) ²³	Mexico	800	51.9 (13.9)	Male 488 (61) Female 312 (39)	Hospital (199 transfer to ICU)	Diabetes 209 (26), obesity 357/797 (44.8), HBP 240 (30), CRD 7 (0.9), asthma 11 (1.4), immunosuppression 48 (6), HIV 10 (1.2), CVD 37 (4.6), CKD 24 (3), CLD 6 (0.8), Smoking 112 (14)	8 (6-10)	Mortality: 241 Morbidity: ARDS 159 (67), MOFS 67
Rodríguez et al. (2020) ³⁵	Spain	43	65.5 (52-72)	Male 27 (62.8) Female 16 (37.2)	ICU	DM 18 (18.6), HBP 13 (30.2), CHD 2 (4.7) IHD 4 (9.3), COPD 4 (9.3), CKD 2 (4.7), obesity 11 (25.6), autoimmune disease 3 (7)	8 (6-10)	Mortality: 10 (23.5), 28 days Morbidity: ARDS 40 (93) Recovery: 28 (60.5)
Pineiro et al. (2021) ³⁶	Spain	52	71.5 (61–74.7)	Male 40 (77) Female 12 (23)	ICU	None 14 (26.9), HBP 31 (59.6), DM 11 (21.2), CHF 2 (3.8), IHD 3 (5.8), obesity 9 (17.3), COPD 11 (21.2), smoker 3 (5.8), cancer 3 (5.8), HIV 1 (1.9), CKD 7 (13.5)	10 (4)	Mortality: 27 (51.92), 35.5 (IQR 36.75) Recovery: 25 (48)
Piowarczyk et al. (2020) ²⁵	Poland	60	ARF group 59 (50–67), Non-ARF group 39 (25–51)	Male 31(51,66) Female 29 (48,33)	Hospital (10 in MV)	HBP 20, COPD 1, diabetes 4, CVD 8, LD 2, CKD 0	7 (4–8)	Mortality: 8 Morbidity: ARDS 22 (36.6)
Radovanovic et al. (2021) ³¹	Italy	2nd p= 76	2 nd p= 68 (55–77)	2 nd p= Male 56 (74) Female 20 (26)	ICU	2 nd p= HBP 33 (43.4), diabetes 23 (30.3), IHD 17 (22.4), CHF 5 (6.6), arrhythmia 7 (9.2), COPD 8 (10.5), asthma 8 (10.5), obesity 9 (11.8), psychiatric disorders 4 (5.3), cancer 7 (9.2), CKD 6 (7.9)	2 nd p= 5 (6–13)	Mortality: 2 nd p= 17 (22.4) Recovery: 42 (55.4)
Roberts et al. (2020) ²⁷	United States	40	61 (52-66)	Male 28 (70) Female 12 (30)	Hospital (11 ICU)	HBP 33 (83), DM 15 (38), CKD 30 (75), CRD 8 (20), asthma 3 (8), HIV 1 (3), HF 9 (23), HLP 14 (35), cancer 1 (3), smoking history 19 (48)	7 (10)	Mortality: 5 (16), 10-28 days Recovery: 23 (72)
Rodriguez-Molinero et al. (2020) ²⁶	Spain	418	65.4 (SD 16.6)	Male 238 (56,9) Female 180 (43,1)	Hospital (254 – severe disease)	CKD 61, HBP 217, DM 99, DLP 145, obesity 74, smoking 36, alcoholism 11, HF 26, IHD 37, atrial fibrillation 45, stroke 2, asthma 23, COPD 41, dementia 43, cancer 48, HIV 3, organ transplant 1	8.0 (SD 4.5)	Mortality: 79, 30 days
Schmidh et al. (2020) ²⁹	France, Switzerland, and Belgium	4244	63 (54–71)	Male 3159 (74.4) Female 1085 (26)	ICU	HBP 2018 (48), DM 1167 (28), immunodeficiency 314 (7)	9 (6–12)	Mortality: 1.298, 90 days Morbidity: ARDS 2233
Taboada et al. (2020) ³⁷	Spain	97	69 (61-73)	Male 62 (63.9) Female 35 (36.08)	ICU	HBP 55 (56.7), DLP 42 (43.3), DM 22 (22.7), asthma 7 (7.2), COPD 11 (11.3), HD 28 (28.9), cancer 7 (7.2), obesity 38 (39.2)	10 (7-12)	Mortality: 15, 42 (34-45) days
Thomson et al. (2020) ⁴⁰	England	156	62 (54-70)	Male 112 (72) Female 44 (28)	ICU	HBP 81, DLP 56, DM 52, IHD 26, CKD 23, CRD 19, end-stage renal failure on dialysis 13	7 (5-10)	Mortality: 38, 30 days Recovery: 82
Yang et al. (2021) ¹⁶	China	357	56.0 (43.0, 68.0)	Male 185 (51.8) Female 172 (48,1)	Hospital	Coexisting disorders 154 (43.1), (including HBP, DM, CRD, CVD or cerebrovascular disease, CKD, HIV metastatic malignancy, CLD)	9.0 (5.0, 15.0)	Mortality: 25, 28 days

Abbreviations: ICU=intensive care unit; ARF=acute respiratory failure; ARDS=acute respiratory distress syndrome; 2nd p= second period; HBP=high blood pressure; DM=diabetes mellitus; DLP=dyslipidemia; IHD=ischemic heart disease; COPD=chronic obstructive pulmonary disease; HT=hypothyroidism; HD=heart disease; CVD=cardiovascular disease; CHF=chronic heart failure; CRD=chronic respiratory diseases; CKD=chronic kidney disease; CLD=chronic liver disease; ILD=interstitial lung disease; LC=liver cirrhosis; HIV=human immunodeficiency virus; CAD=coronary artery disease; KD=kidney disease; HLP=hyperlipidemia; SD=standard deviation; IQR=interquartile range.


Table S4. Distribution of patients for setting and outcomes prevalence.

Setting	Transfer to		Mortality	Morbidity		Recovery
	No	ICU/ MV	No	MOFS No	ARDS No	No
Hospital ward	4325	1407	916	412/2,869	229/ 1,045	991/ 1,445
ICU	9392	-	3,457	487/3,264	3,710/ 7,625	1,531/3,133
Total	13,717	1407	4,373	899/6,133	3,939/ 8,670	2,522/ 4,578


Abbreviations: ICU=intensive care unit; MV=mechanical ventilation; MOFS=multiorgan failure syndrome; ARDS=acute respiratory distress syndrome.

Figure S1. Prevalence of hypertension in the sample.


For analysis, the studies were grouped by country and by hospital setting (hospital ward or ICU). Estimates of proportions for dichotomous data, considering number of events and sample size, were reported. Abbreviations: ICU=intensive care unit; CI=confidence interval; USA=United States of America; UK=United Kingdom.

Figure S2. Prevalence of diabetes in the sample.

For analysis, the studies were grouped by country and by hospital setting (hospital ward or ICU). Estimates of proportions for dichotomous data, considering number of events and sample size, were reported. Abbreviations: ICU=intensive care unit; CI=confidence interval; USA=United States of America; UK=United Kingdom.

Figure S3. Prevalence of obesity in the sample.

For analysis, the studies were grouped by country and by hospital setting (hospital ward or ICU). Estimates of proportions for dichotomous data, considering number of events and sample size, were reported. Abbreviations: ICU=intensive care unit; CI=confidence interval.

Figure S4. Prevalence of smoking history in the sample.

For analysis, the studies were grouped by country and by hospital setting (hospital ward or ICU). Estimates of proportions for dichotomous data, considering number of events and sample size, were reported. Abbreviations: ICU=intensive care unit; CI=confidence interval; USA=United States of America.

Table S5. Risk of bias assessment (QUIPS)

Study	Study Participation	Study Attrition	Prognostic Factor Measurement	Outcome Measurement	Study Confounding	Statistical Analysis and Reporting
Allenbach et al. ²⁰	Moderate	Low	N/A	Low	Moderate	Low
Barrasa et al. ³⁴	Moderate	Low	N/A	Low	High	Moderate
Brandão et al. ¹⁴	Moderate	Low	N/A	Low	Moderate	Low
Cao et al. ¹⁵	Moderate	Low	N/A	Moderate	High	Moderate
Cortes-Telles et al. ²²	Moderate	Low	N/A	Moderate	Moderate	Low
Cummings et al. ⁴³	Moderate	Moderate	N/A	Low	Moderate	Low
Dzupová et al. ²⁸	Low	Low	N/A	Moderate	High	Moderate
Estella et al. ³³	Low	Moderate	N/A	Low	Moderate	Low
Ferrando et al. ³⁸	Low	Moderate	N/A	Moderate	High	Low
Giacomelli et al. ²¹	Moderate	Low	N/A	Low	Moderate	Low
Gupta et al. ⁴¹	Moderate	Low	N/A	Low	Moderate	Low
Jourdes et al. ¹⁸	Moderate	Low	N/A	Low	High	Moderate
Kaeuffer et al. ¹⁹	Moderate	Low	N/A	Low	Moderate	Low
Kayina et al. ³⁰	Moderate	Moderate	N/A	Low	High	Moderate
Larsson et al. ³⁹	Moderate	Low	N/A	Low	Moderate	Low
Madsen et al. ¹⁷	Low	Low	N/A	Low	High	Moderate
Molnar et al. ⁴²	Moderate	Low	N/A	Low	High	Moderate
Myrstad et al. ²⁴	Moderate	Low	N/A	Low	High	Low
Namendys-Silva et al. ³²	Moderate	Moderate	N/A	Low	Moderate	Low
Olivas-Martinez et al. ²³	Moderate	Moderate	N/A	Low	Moderate	Low
Rodríguez et al. ³⁵	Moderate	Low	N/A	Low	High	Moderate
Pineiro et al. ³⁶	Low	Low	N/A	Low	Moderate	Low
Piwowarczyk et al. ²⁵	Low	Low	N/A	Moderate	High	Low
Radovanovic et al. ³¹	Moderate	Low	N/A	Moderate	High	Low
Roberts et al. ²⁷	Moderate	Low	N/A	Low	High	Moderate
Rodriguez-Molinero et al. ²⁶	Moderate	Low	N/A	Low	Moderate	Low
Schmidt et al. ²⁹	Moderate	High	N/A	Low	Moderate	Low
Taboada et al. ³⁷	Moderate	Low	N/A	Low	High	Moderate
Thomson et al. ⁴⁰	Moderate	Low	N/A	Low	Moderate	Low
Yang et al. ¹⁶	Moderate	Low	N/A	Low	High	Low

Low: low risk of bias, Moderate: moderate risk of bias, High: high risk of bias. N/A: not applicable. The risk of bias was determined by judging the warming items for each domain.